Evidence map›Paper›PMID 41589855›Full record

ArticleAntimicrobial agents and chemotherapy2026

Case Commentary: Intraventricular polymyxin B-small steps, big questions.

Nitin Das Kunnathu Puthanveedu, Adarsh Bhimraj

Abstract readComment
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nitin Das Kunnathu PuthanveeduSection of Infectious Diseases, Department of Internal Medicine, University of Illinois College of Medicine, Peoria, Illinois, USA.ORCID 0000-0001-8656-1519
Adarsh BhimrajDivision of Infectious Diseases, Department of Internal Medicine, Houston Methodist Hospital, Houston, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistant gram-negative ventriculitis is a life-threatening infection with limited treatment options. H. Jiang, Y. Hu, J. Cai, J. Zhang, et al. (Antimicrob Agents Chemother 70:e00943-25, 2026, https://doi.org/10.1128/aac.00943-25) describe two patients with this condition who were successfully treated with intraventricular polymyxin B. Their report highlights uneven antibiotic distribution within the ventricles, the influence of cerebrospinal fluid drainage on intraventricular drug concentrations, and cure with intraventricular polymyxin B alone. These findings raise important questions about optimal intraventricular antimicrobial dosing and whether concurrent intravenous therapy is needed in healthcare-associated ventriculitis.

Indexed as

Anti-Bacterial AgentsCerebral VentriculitisPolymyxin BCase Reports as TopicFemaleHumansAnti-Bacterial AgentsPolymyxin BHCAVMhealthcare-associated ventriculitis and meningitisintraventricular therapypharmacokineticspolymyxinsventriculitis

Identifiers

PMID41589855
PMCPMC12998942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.